IP Library Granted Patent US 10,206,941
Granted Patent B2
US 10,206,941 · App. 14/903,899 · Granted Feb 19, 2019

Venule endothelial cell genes and uses thereof

Inventors: Ulrich H. von Andrian (Brookline, MA); Aude Thiriot (Brookline, MA); Omid Farokhzad (Waban, MA); Jinjun Shi (Boston, MA)
Assignees: President and Fellows of Harvard College; The Brigham and Women's Hospital, Inc.
A61K31/713A61K47/543A61K47/6929C07K14/47C12Q1/6881A61K48/00C12Q2600/136C12Q2600/158C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,206,941
App. No.
14/903,899
Granted
Feb 19, 2019
Kind
B2
Abstract

Disclosed herein are genes which are differentially expressed in venule endothelial cells (V-ECs) compared to non-venule endothelial cells (NV-ECs) and methods and compositions relating to those genes. Also disclosed herein are methods of modulating the venuleness of an endothelial cell or microvessel, methods of modulating leukocyte trafficking, methods of modulating inflammation, methods of targeting agents to tissues based on their ability to bind to surface markers expressed in a microvessel (e.g., venules and non-venules), methods of identifying the venuleness of endothelial cells or microvessels, methods of identifying agents that modulate the venuleness of endothelial cells or microvessels, methods of identifying agents that target microvessels, methods for treating diseases associated with leukocyte trafficking, methods for treating inflammatory diseases, and compositions and kits for use in the methods.

Claims (4)

1. A method of decreasing venuleness in a subject in need thereof, comprising:

administering to the subject an effective amount of an agent that decreases expression of Zfp521.

2. The method according to claim 1 , wherein Zfp521 is differentially expressed in skin venule endothelial cells compared to skin non-venule endothelial cells, or wherein Zfp521 is differentially expressed in adipose tissue venule endothelial cells compared to adipose tissue non-venule endothelial cells, or

wherein Zfp521 is differentially expressed in lymph node venule endothelial cells compared to lymph node non-venule endothelial cells.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 13, 2016
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 038971/0037 →
Continuity (2)
Provisional Application 61844372 · Jul 9, 2013
Related Publication 20160354403A1 · Dec 8, 2016